Aktualności
 
The 4th International Conference on Prehypertension, Hypertension and Cardio Metabolic Syndrome
 
16.01.2015
The 4th International Conference on Prehypertension, Hypertension and Cardio Metabolic Syndrome will take place in Venice, Italy from 3-6 March, 2016.
 
Healthcare integrated biobanking and multiomics biomarker analysis
 
02.05.2014
We would like to announce the International Conference “Healthcare integrated biobanking and multiomics biomarker analysis“ held in Regensburg during July 3-5, 2014.
 
The 2nd World Congress of Clinical Lipidology
 
21.04.2014
Dear Colleagues,
It is our pleasure to invite you to participate in The 2nd World Congress of Clinical Lipidology, which will take place in Vienna, Austria from 5-7 December, 2014.
 
III Kongres Polskiego Towarzystwa Lipidologicznego (PTL)
 
23.07.2013
Mam ogromną przyjemność zaprosić Państwa na III Kongres Polskiego Towarzystwa Lipidologicznego (PTL), który odbędzie się w Warszawie w dniach 11-12 października 2013 roku.
 
Wywiad z Prof. Maciejem Banachem na temat aktualnych wyzwań w leczeniu zaburzeń lipidowych.
 
06.07.2013
Wywiad w trakcie spotkania ekspertów lipidowych w Barcelonie w czerwcu 2013 roku.
 
Nowe rekomendacje FDA dotyczące bezpieczeństwa stosowania statyn
 
13.03.2012
The FDA now recommends that clinicians test liver enzymes in their patients before prescribing statin treatment and as clinically indicated thereafter, rather than routinely monitoring liver enzymes as was recommended previously. Statin treatment should be interrupted in patients who develop serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice, and drug therapy should not resume unless an alternate cause is found for the hepatic dysfunction. Statin use may rarely be associated with mild, generally reversible symptoms of cognitive impairment, with variable time to symptom onset and resolution of symptoms on statin discontinuation. Statin use has also been associated with increases in levels of fasting serum glucose and HbA1c. The updated safety label for lovastatin now includes new contraindications and dose limitations when the drug is given concurrently with certain medications that can increase the risk for myopathy and/or rhabdomyolysis.
 
Strona:    1   2   Następna
Polish Lipid Association
ul. Kleeberga 2
61-615 Poznań
tel./faks: +48 61 822 77 81
© 2011 Polish Lipid Association. All rights reserved.